AMEX · Medical - Diagnostics & Research

VolitionRX Ltd (VNRX) Stock

$0.92 -8.26% AMEX: VNRX Healthcare

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes.

Valuation

MetricValue
Price$0.92
Market Cap$7.65M
P/E Ratio-0.24
P/B Ratio-0.22
P/S Ratio3.38
EPS (TTM)$-4.40
52-Week High$16.00
52-Week Low$0.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE74.16%
ROA-272.21%
ROCE446.48%
Gross Margin-1050.00%
Operating Margin-1050.00%
Net Margin-997.46%
Debt/Equity-0.36
Current Ratio0.17

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$1.0M$1.0M$2.0M
Operating Profit$-28.0M$-32.0M$-36.0M$-27.0M$-21.0M
Net Profit$-27.0M$-30.0M$-35.0M$-27.0M$-23.0M
EPS$-10.20$-11.00$-10.00$-6.20$-4.40
Op Margin-31469.0%-10372.4%-4641.8%-2190.9%-1228.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$27.0M$18.0M$28.0M$9.0M$7.0M
Total Liabilities$10.0M$21.0M$37.0M$36.0M$42.0M
Cash$21.0M$11.0M$21.0M$3.0M$1.0M
Borrowings$4.0M$5.0M$6.0M$6.0M$11.0M

Latest News

VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution Simply Wall St. · Jul 12, 2026 VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test PR Newswire · Jul 7, 2026 VolitionRx Announces Collaboration with Sysmex PR Newswire · Jun 17, 2026 VolitionRx Announces Pricing of $4.6 Million Public Offering PR Newswire · Jun 7, 2026 VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring PR Newswire · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-21.0M$-15.0M$-18.0M$-26.0M$-20.0M
Investing Cash Flow$-2.0M$-3.0M$-2.0M$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$1.0M$-10.0M$10.0M$-17.0M$-2.0M
Free Cash Flow$-22.0M$-17.0M$-19.0M$-26.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-0.76
FCF Yield-261.37%
Quick Ratio0.17
Interest Coverage-10.50
Return 1Y-90.92%
Return 3Y-95.76%
Return 5Y-98.05%

Ownership

Insiders Held8.62%
Institutions Held20.80%
Institutions Float Held22.76%
Institutional HolderSharesReport Date
Lagoda Investment Management, L.P.807,4502026-03-31
Geode Capital Management, LLC61,5042026-03-31
Vanguard Capital Management LLC50,6842026-03-31
Luminus Management, LLC49,7502026-03-31
State Street Corporation33,9972026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
BDSX $20.38 -3.09% -2.82 $165.90M 0.00%
CTSO $0.35 -4.32% -3.62 $22.25M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%
MDCX $0.28 -12.01% -0.71 $6.17M 0.00%

About VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

VolitionRX Ltd is led by CEO Cameron Reynolds, employs 85 people, headquartered in US, publicly traded since 2012.

VolitionRX Ltd (VNRX) stock trades at $0.92 with a market capitalization of $7.65M. The stock is valued at a price-to-earnings (P/E) ratio of -0.24, price-to-book of -0.22, price-to-sales of 3.38. Over the past 52 weeks the stock has ranged between $0.88 and $16.00, and currently trades 94.3% below its 52-week high.

On profitability, VolitionRX Ltd generates a return on equity (ROE) of 74.16% — well above the market average, a sign of a high-quality business, return on capital employed of 446.48%, an operating margin of -1050.00%, a net profit margin of -997.46%.

Official website: volition.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides